公开(公告)号：US20170035822A1

公开(公告)日：2017-02-09

申请号：US15304316

申请日：2015-04-17

Applicant: Korea Research Institute of Bioscience and Biotechnology

Inventor： Sei Ryang OH ,  Kyung Seop AHN ,  Seung Hyung KIM ,  In Sik SHIN ,  Hang JIN ,  Jung Hee KIM ,  Hyung Won RYU ,  Wan Yi LI ,  Sang Woo LEE ,  Joong Ku LEE ,  Sang Ho CHOI

IPC: A61K36/22 ,  A61K9/00 ,  A23L33/105 ,  A61K31/12

Abstract: The present invention relates to a composition for suppressing chronic obstructive pulmonary disease (COPD) comprising a Pistacia weinmannifolia extract, a fraction thereof, or a compound isolated therefrom and, more particularly, to a pharmaceutical composition for preventing or treating COPD comprising a Pistacia weinmannifolia extract, a fraction thereof, or a compound isolated therefrom; a food composition for preventing or improving COPD, and the compound isolated therefrom. The composition comprising a Pistacia weinmannifolia extract, a fraction thereof, or a compound isolated therefrom, according to the present invention, is not toxic, suppresses the invasion of inflammatory cells into the bronchial tube of a COPD-induced animal model, and effectively suppresses the expression of CXCL-1, TNF-α, or MIP-2. In addition, due to the use of a safety-proven herbal drug as a raw material, the composition of the present invention can resolve various side-effects of existing therapeutic agents for COPD, chronic obstructive bronchitis, chronic bronchiolitis, emphysema, multiple sclerosis, and acute and chronic inflammation, and thus can be effectively used as a composition for preventing, treating and remedying COPD.

Abstract translation: 本发明涉及一种抑制慢性阻塞性肺疾病（COPD）的组合物，其包含维斯特氏菌提取物，其分数或从其分离的化合物，更具体地，涉及用于预防或治疗COPD的药物组合物，所述药物组合物包含猕猴桃提取物（Pistacia weinmannifolia extract） ，其一部分，或从其分离的化合物; 用于预防或改善COPD的食物组合物和从其分离的化合物。 根据本发明的包含猕猴桃提取物，其馏分或从其分离的化合物的组合物是无毒的，抑制炎性细胞侵入COPD诱导的动物模型的支气管中，并有效地抑制 CXCL-1，TNF-α或MIP-2的表达。 此外，由于使用经安全验证的草药作为原料，本发明的组合物可以解决现有的COPD治疗剂，慢性阻塞性支气管炎，慢性细支气管炎，肺气肿，多发性硬化症， 和急性和慢性炎症，因此可以有效地用作预防，治疗和治疗COPD的组合物。

公开(公告)号：US20160228402A1

公开(公告)日：2016-08-11

申请号：US15022546

申请日：2013-11-08

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Sei Ryang OH ,  Yong Yeon CHO ,  Hyung Won RYU ,  Cheol Jung LEE ,  Hye Suk LEE ,  Doo Young KIM ,  Jung Hee KIM ,  Kyung Seop AHN ,  Mee Hyun LEE ,  Hyeong Kyu LEE

IPC: A61K31/34 ,  A61K45/06 ,  A61K36/898

CPC classification number: A61K31/34 ,  A23V2002/00 ,  A61K31/05 ,  A61K31/36 ,  A61K36/575 ,  A61K36/898 ,  A61K45/06 ,  A61K2300/00 ,  A23V2200/308 ,  A23V2250/21 ,  A61K31/06

Abstract: The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating cancer. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating cancer including a lignan compound having a specific chemical structure (Chemical Formula 1); a health functional food composition for preventing or ameliorating cancer including the lignan compound; and a method for preventing, ameliorating, or treating cancer using the composition.Further, the present invention relates to a use of the lignan compound in the preparation of a pharmaceutical composition or a health functional food composition for preventing, ameliorating, or treating cancer.

Abstract translation: 本发明涉及用于预防，改善或治疗癌症的药物组合物。 更具体地说，本发明涉及包含具有特定化学结构的木脂素化合物（化学式1）的用于预防或治疗癌症的药物组合物。 一种用于预防或改善包括木脂素化合物在内的癌症的健康功能性食品组合物; 以及使用该组合物预防，改善或治疗癌症的方法。 此外，本发明涉及木素素化合物在制备用于预防，改善或治疗癌症的药物组合物或保健功能性食品组合物中的用途。

公开(公告)号：US20160051612A1

公开(公告)日：2016-02-25

申请号：US14780503

申请日：2014-04-09

Applicant: YUNGJIN PHARMACEUTICAL CO., LTD. ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Yongnam LEE ,  Ji-seok YOO ,  Dae-hee SHIN ,  Byung-hwan RYOO ,  Kyung Seop AHN ,  Sei Ryang OH ,  Hyeong Kyu LEE ,  In Sik SHIN ,  Doo Young KIM ,  Ok-Kyoung KWON ,  Hyuk Hwan SONG ,  Seung Hyung KIM ,  SuUi LEE

IPC: A61K36/68 ,  A61K31/192 ,  A61K31/7048

CPC classification number: A61K31/192 ,  A23L33/105 ,  A61K31/194 ,  A61K31/7048 ,  A61K36/80 ,  A61K2236/00

Abstract: A composition comprising a purified extract isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient or the compounds isolated therefrom as an active ingredient for treating a chronic obstructive pulmonary disease and the use thereof. Inventive purified extract and compounds showed potent anti-COPD activity without beta-2-receptor agonistic response through various in vivo tests as well as in vitro test. Therefore, it can be used as the therapeutics or functional health food for treating and preventing chronic obstructive pulmonary disease (COPD).

Abstract translation: 一种组合物，其包含从Pseudolysimachion rotundum var。 含有大量活性成分的亚结构或从其分离的化合物作为治疗慢性阻塞性肺部疾病的活性成分及其用途。 发明纯化的提取物和化合物通过各种体内试验以及体外试验显示出有效的抗COPD活性，而没有β-2-受体激动反应。 因此，它可以用作治疗和预防慢性阻塞性肺疾病（COPD）的治疗剂或功能性保健食品。

公开(公告)号：US20230364170A1

公开(公告)日：2023-11-16

申请号：US18024604

申请日：2021-08-18

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Su Ui LEE ,  Hyung Won RYU ,  Mun Ock KIM ,  Sei Ryang OH ,  Doo Young KIM ,  Hyun Jae JANG

IPC: A61K36/258 ,  A61K31/585 ,  A61K36/38 ,  A61K31/194 ,  A61P3/08 ,  A61P3/04

CPC classification number: A61K36/258 ,  A61K31/585 ,  A61K36/38 ,  A61K31/194 ,  A61P3/08 ,  A61P3/04

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating obesity or diabetes, and to a food composition and feed composition for preventing or alleviating obesity or diabetes, comprising as an active ingredient, an Acanthopanax extract, a garcinia cambogia extract, or compounds isolated therefrom. The composition has synergistic antidiabetic and antiobesity activity compared to that of using only an Acanthopanax extract, a garcinia cambogia extract, or compounds isolated therefrom. Therefore, it is possible to reduce the possibility of any side effects that may be caused by an overdose of or long-term administration of the garcinia cambogia extract and a substance isolated therefrom, and thus the composition can be very effectively utilized in the development of a therapeutic agent for diabetes or obesity.

公开(公告)号：US20170266142A1

公开(公告)日：2017-09-21

申请号：US15384302

申请日：2016-12-19

Applicant: YUNGJIN PHARMACEUTICAL CO., LTD ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Yongnam LEE ,  Ji-seok YOO ,  Dae-hee SHIN ,  Byung-hwan RYOO ,  Kyung Seop AHN ,  Sei Ryang OH ,  Hyeong Kyu LEE ,  In Sik SHIN ,  Doo Young KIM ,  Ok-Kyoung KWON ,  Hyuk Hwan SONG ,  Seung Hyung KIM ,  SuUi LEE

IPC: A61K31/192 ,  A61K36/80 ,  A61K31/7048 ,  A23L33/105 ,  A61K31/194

CPC classification number: A61K31/192 ,  A23L33/105 ,  A61K31/194 ,  A61K31/7048 ,  A61K36/80 ,  A61K2236/00

Abstract: A composition comprising a purified extract isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient or the compounds isolated therefrom as an active ingredient for treating a chronic obstructive pulmonary disease and the use thereof. Inventive purified extract and compounds showed potent anti-COPD activity without beta-2-receptor agonistic response through various in vivo tests as well as in vitro test. Therefore, it can be used as the therapeutics or functional health food for treating and preventing chronic obstructive pulmonary disease (COPD).

公开(公告)号：US20160199338A1

公开(公告)日：2016-07-14

申请号：US14912049

申请日：2014-08-18

Applicant: ENZYCHEM LIFESCIENCES CORPORATION ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Jae Wha KIM ,  Sei Ryang OH ,  Kyung Seop AHN ,  Ho Bum KANG ,  Beom Su PARK ,  Tae Suk LEE ,  Jong Koo KANG ,  Young Sik JUNG ,  Yong-Hae HAN ,  Ki-Young SOHN

IPC: A61K31/231 ,  A61K9/48 ,  A61K9/00

CPC classification number: A61K31/231 ,  A61K9/0053 ,  A61K9/4825 ,  A61K31/23

Abstract: The invention relates to pharmaceutical compositions, as well as health functional food compositions and quasi-drug compositions, for preventing, treating, or improving rheumatoid arthritis, comprising a monoacetyldiacylglycerol compound as an active ingredient. The monoacetyldiacylglycerol of the invention is effective in inhibiting the phosphorylation of STAT-3 known to be a therapeutic target for rheumatoid arthritis. As the monoacetyldiacylglycerol is an effective therapeutic agent without toxicity, the monoacetyldiacylglycerol can overcome the side effects of the medicines currently used in the treatment of rheumatoid arthritis. Thus, the monoacetyldiacylglycerol can be used for preventing, treating or improving rheumatoid arthritis.